Neurocrine's Next Move: Crinecerfont Trial Targets CAH in Infants

SAN DIEGO, CA – July 01, 2026 – Neurocrine Biosciences has fired the starting gun on a pivotal Phase 2 clinical study for its drug crinecerfont, targeting the youngest and most vulnerable patients with classic congenital adrenal hyperplasia (CAH). The trial, focused on children from 3 months to under 4 years old, represents a significant strategic push to expand the market for a therapy that already marked the first major innovation in the field in over 70 years. For families navigating this rare genetic disorder, the study offers a glimmer of hope for a future less dependent on the high-dose steroids that have long defined treatment.

The San Diego-based biopharma company announced the initiation of the study today, aiming to establish the safety and tolerability of CRENESSITY® (crinecerfont) in this fragile pediatric group. If successful, the move could not only transform the standard of care from birth but also cement Neurocrine's position in an increasingly competitive endocrine market, demonstrating a clear strategy to maximize the drug's lifecycle by addressing a profound unmet need at its earliest point.

The Decades-Old Dilemma in Pediatric CAH

To grasp the significance of this trial, one must first understand the brutal balancing act that defines life with classic CAH. This inherited disorder cripples the adrenal glands' ability to produce essential hormones, most notably cortisol. Without this crucial stress hormone, the body is left defenseless against illness or injury, creating the constant threat of a life-threatening “adrenal crisis.”

Compounding this deficiency, the body’s hormonal factory, in its failed attempt to produce cortisol, churns out an excess of androgens, or male sex hormones. This hormonal imbalance creates a cascade of complications, from ambiguous genitalia in newborn females to accelerated growth in childhood that paradoxically leads to short stature in adulthood. The standard treatment for decades has been a double-edged sword: lifelong glucocorticoid (steroid) replacement. While necessary to provide the missing cortisol, steroids have also been used in supraphysiologic—or unnaturally high—doses to suppress the pituitary gland's signal that drives androgen overproduction.

For infants and toddlers in a critical window of brain and body development, this high-dose steroid exposure is particularly damaging. The treatment is associated with a host of metabolic and cardiovascular issues, including weight gain, insulin resistance, and hypertension, along with impaired bone growth. For parents, it's a daily struggle of managing medication schedules, monitoring for signs of crisis, and worrying about the long-term consequences of the very treatment keeping their child alive. Until the approval of crinecerfont, there were no approved therapies to specifically address the androgen excess without this reliance on high-dose steroids.

A New Mechanism for a New Era

Crinecerfont's 2024 approval for adults and children aged 4 and older heralded a paradigm shift. Unlike steroids, which act as a blunt instrument, crinecerfont is a potent and selective oral corticotropin-releasing factor type 1 (CRF1) antagonist. It works upstream by blocking the hormonal signals in the pituitary that lead to androgen overproduction. By targeting the source, it allows for a reduction in the daily steroid dose to more physiologic levels, aiming only to replace the cortisol the body cannot make on its own.

Data from the drug's pivotal CAHtalyst studies in older populations have been compelling. Results showed that patients could significantly lower their daily glucocorticoid dose while maintaining or improving control of their androgen levels. Furthermore, recent two-year data from the pediatric study demonstrated durable androgen control and meaningful improvements in clinical outcomes like body mass index and insulin resistance—direct counterpunches to the known side effects of long-term steroid use.

"Infants and young children with classic CAH face significant health challenges and are often exposed to high doses of glucocorticoids during critical periods of growth and development," said Dr. Sanjay Keswani, Chief Medical Officer at Neurocrine Biosciences, in the company's official statement. "The initiation of this Phase 2 study reflects our commitment to evaluating crinecerfont as a potential treatment option that could reduce the need for long-term supraphysiologic glucocorticoid use and help mitigate the associated risks in this vulnerable, very young population."

The Path to a Broader Indication

The new Phase 2 study is a meticulously designed step toward that goal. The open-label, single-arm trial will enroll 20 participants for a 24-week treatment period, with a primary focus on safety and tolerability. Secondary objectives will assess how the drug is processed by these tiny bodies (pharmacokinetics) and its effect on key hormone biomarkers.

Critically, Neurocrine is conducting this study under an FDA Pediatric Written Request. This is a key regulatory mechanism the FDA uses to incentivize the study of drugs in children, often granting an additional period of market exclusivity upon approval. This highlights the trial's dual purpose: it is both a scientific necessity to ensure safety in a new population and a shrewd business move to extend the drug's commercial runway. A successful outcome is expected to support a supplemental New Drug Application (sNDA) to formally expand CRENESSITY's label to include patients from infancy.

The company's strategy appears to be global in scope, with target enrollment already achieved for a similar Phase 2 study in the European Union evaluating crinecerfont in children from birth to under 2 years of age. This parallel effort suggests a coordinated push to establish the drug as the worldwide standard of care for CAH across all age groups.

Reshaping the Competitive and Human Landscape

While Neurocrine was the first to market with a novel mechanism, the CAH space is not without competition. Companies like Crinetics Pharmaceuticals and Spruce Biosciences are advancing their own novel antagonists, signaling a broader industry recognition of the market opportunity in moving beyond steroids. By pushing into the infant population, Neurocrine is building a strategic moat. Establishing CRENESSITY as a first-line therapy from birth could create a generation of patients and physicians loyal to the treatment, making it harder for later entrants to gain market share.

For the CAH community, the market dynamics are secondary to the profound human impact. Patient advocacy groups have long highlighted the immense burden the condition places on families. The prospect of a therapy that can more safely manage the disease from its earliest days is transformative. As one parent noted in an online forum, the hope is for a treatment that allows their child “to just be a kid,” without the constant shadow of steroid side effects looming over their growth and future health.

This new trial represents the early innings of that potential reality. If crinecerfont proves safe and effective in infants, it could fundamentally alter the trajectory of a CAH diagnosis, promising not just survival, but a healthier and more manageable life from the very beginning.